Lusutrombopag - Latest Advances

Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.

Journal: BMJ open

Published: August 10, 2025

Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study.

Journal: Internal medicine (Tokyo, Japan)

Published: March 16, 2025

Development and validation of a prognostic prediction model based on coagulation-related genes and clinical factors in acute leukemia.

Journal: Translational pediatrics

Published: February 21, 2025

QSAR-Based Drug Repurposing and RNA-Seq Metabolic Networks Highlight Treatment Opportunities for Hepatocellular Carcinoma Through Pyrimidine Starvation.

Journal: Cancers

Published: January 27, 2025

Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: November 11, 2024

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: October 29, 2024

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.

Journal: Journal of pharmaceutical health care and sciences

Published: September 02, 2024

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.

Journal: Hamostaseologie

Published: June 26, 2024

Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.

Journal: Journal of clinical medicine

Published: May 21, 2024

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus.

Journal: ACS infectious diseases

Published: April 03, 2024

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis.

Journal: Heliyon

Published: September 10, 2023

Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.

Journal: Digestive diseases (Basel, Switzerland)

Published: June 23, 2023

Filters

Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.

Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.

Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study.

Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study.

Development and validation of a prognostic prediction model based on coagulation-related genes and clinical factors in acute leukemia.

Development and validation of a prognostic prediction model based on coagulation-related genes and clinical factors in acute leukemia.

QSAR-Based Drug Repurposing and RNA-Seq Metabolic Networks Highlight Treatment Opportunities for Hepatocellular Carcinoma Through Pyrimidine Starvation.

QSAR-Based Drug Repurposing and RNA-Seq Metabolic Networks Highlight Treatment Opportunities for Hepatocellular Carcinoma Through Pyrimidine Starvation.

Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease

Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study.

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study.

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.

Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.

Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus.

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus.

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis.

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis.

Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.

Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.